Day 2: #ASCVD
Zurich Heart House (ZHH) Prof Kausik Ray FMedSci 👏

Many candidates to be ordinary member responsible for National Societies. Nice to see ⁦Dr Meral Kayikcioglu⁩ qualified for the final

A patient I saw “there is a lot of misinformation about LDL cholesterol. What convinced me were the Mendelian Randomisation studies”
😳🤷🏽‍♂️👍

Colombian Association of Endocrinology , Diabetes and Metabolism. Decent nights sleep now 3 talks including closing keynote.
Cartagena

Returning home to these scented flowers softened the blow of a return from holiday

So after 10 days at the ITC Windsor the fantastic chef offered to cook anything I wanted. I went for a typical Bengali set of dishes.
If you know you know….on the house too! Thank you India for the rest and the nourishment

Richard Ferraro Hooman Bakhshi Bailey Ann Estes SABOURETCardiologist Giuseppe Biondi-Zoccai Implausibly large effect sizes with sparse events are seldom replicable.

🧐Enjoy our work introducing #inclisiran
🎯Find out its unique mechanism, efficiencysafety profile supported by robust clinical trials.
🚀Inclisiran emerges as a first-in-class breakthrough in lipid-lowering therapies
#ASCVD #cholesterol Prof Kausik Ray FMedSci
tandfonline.com/doi/full/10.10…

4a) So we'll start with some updates on the seminal #CLEAR_Outcomes trial. Don't recall that? Refresh your memory & earn even more 🆓 #MedEd credit 🇺🇸🇨🇦🇪🇺🇬🇧from experts C. Michael Gibson MD Christopher Cannon, M.D. 🇺🇦 Pam R. Taub, MD❤️💃🏻 Erin D. Michos, M.D. Prof Kausik Ray FMedSci at cardiometabolic-ce.com/category/lipid….

Something many of us thought likely now proven. Great to see this important trial completed

We are engineering the future of genetic medicine to enable #HealthForAll .

To do this, we are developing in vivo #CRISPR -based genetic medicines that can become standard of care treatments for highly prevalent diseases. Learn more this #WorldHealthDay at scribetx.com.

A median 63.4% reduction in LDL-C was observed in patients receiving a combination of our potent CETP inhibitor, obicetrapib, and ezetimibe on top of high-intensity statins in our Phase 2 ROSE2 study. Our pivotal Phase 3 trial, TANDEM, will evaluate a fixed-dose combination of…

#ACC24 Gregory Schwartz reminds ud that Ezetimibe is still underutilized and can add substantial benefits to reduce ASCVD outcomes when added to statins or other LDLc lowering therapies! #CardioTwitter #Cardiology

Moved to Bengaluru! I will be eating my way through the various items on the menu at several fabulous restaurants at the ITC Windsor Manor. Colonial Style decor such an amazing selection of restaurants

Siyab Panhwar, MD Sadly, way too many clinicians including cardiologists are unaware of primordial prevention and ignore pathological lipid metrics. The sooner we attack causal ASCVD risk factors the better. Too many will wait a few decades until a + CAC or CTA or worse (MACE) occurs.

#Statin therapy produces a small increase in #glycaemia , which translates into a moderate increase in the rate at which individuals are diagnosed with new-onset #diabetes (or worsening glycaemic control among those with diabetes) thelancet.com/journals/landi…
#OpenAccess